Zai Lab Limited (ZLAB)Healthcare | Biotechnology | Pudong, China | NasdaqGM
24.99 USD
+0.18
(0.726%)
⇧
(Oct. 9, 2026, 4 p.m.
EDT)
After hours: 24.99 |
Hot Take ↕ | Oct. 10, 2026, 6:29 a.m. EDT
The investment case for Zai Lab is currently fractured by deteriorating fundamentals and a lack of financial discipline. Despite a 'strong buy' analyst consensus driven by the company's oncology pipeline, the financial reality is stark: revenue is shrinking by 3.3%, operating margins are deeply negative at -72%, and the company is burning cash with no free cash flow generation. The balance sheet is fragile, with debt-to-equity nearing 42% and negative returns on both assets and equity. The price action reflects this uncertainty. While the stock has recovered somewhat from its lows, the trailing twelve-month performance shows a net decline, and the recent price history reveals a volatile, range-bound struggle without a clear upward trend. The absence of any dividend history confirms the company is reinvesting all capital into operations, which is standard for biotech but risky given the current burn rate. Options activity provides the clearest signal of market sentiment: traders are aggressively buying cheap put protection at strikes significantly below the current price, betting on further downside. This defensive positioning overrides the optimistic analyst targets, suggesting the market sees the current valuation as insufficiently safe against potential clinical setbacks or continued revenue erosion. Until the company demonstrates a path to profitability or stabilizes its revenue growth, the risk-reward profile remains skewed toward caution. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.307660 |
| AutoARIMA | 0.312276 |
| AutoETS | 0.312278 |
| AutoTheta | 0.328396 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 1.17 |
| Ljung-Box p | 0.016 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 12.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 41.937 |
| Revenue per Share | 4.057 |
| Market Cap | 2,805,532,928 |
| Forward P/E | -11.84 |
| Beta | 0.72 |
| Profit Margins | -41.86% |
| Website | https://www.zailaboratory.com |
As of Oct. 10, 2026, 6:29 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes 17.5 and 20) expiring late in 2026 and early 2027. This 'insurance' positioning suggests a fear of significant further declines. Conversely, call activity is concentrated near the money and slightly out-of-the-money, indicating a limited bullish thesis focused on modest recovery rather than a major breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.19980788 |
| Address1 | Building B |
| Address2 | 899 Halei Road |
| All Time High | 193.54 |
| All Time Low | 13.48 |
| Ask | 23.88 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 805,720 |
| Average Daily Volume3 Month | 942,931 |
| Average Volume | 942,931 |
| Average Volume10Days | 805,720 |
| Beta | 0.724 |
| Bid | 13.12 |
| Bid Size | 2 |
| Book Value | 5.408 |
| City | Pudong |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 24.99 |
| Current Ratio | 2.133 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,789,430,400 |
| Day High | 25.88 |
| Day Low | 24.35 |
| Debt To Equity | 41.937 |
| Display Name | Zai Lab |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -248,168,000 |
| Ebitda Margins | -0.55196 |
| Enterprise To Ebitda | -9.987 |
| Enterprise To Revenue | 5.513 |
| Enterprise Value | 2,478,512,128 |
| Eps Current Year | -2.1956 |
| Eps Forward | -2.11033 |
| Eps Trailing Twelve Months | -1.7 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.8734 |
| Fifty Day Average Change | 0.11660004 |
| Fifty Day Average Change Percent | 0.00468774 |
| Fifty Two Week Change Percent | -19.98079 |
| Fifty Two Week High | 31.85 |
| Fifty Two Week High Change | -6.8600006 |
| Fifty Two Week High Change Percent | -0.21538463 |
| Fifty Two Week Low | 15.96 |
| Fifty Two Week Low Change | 9.03 |
| Fifty Two Week Low Change Percent | 0.56578946 |
| Fifty Two Week Range | 15.96 - 31.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 97,110,287 |
| Forward Eps | -2.11033 |
| Forward P E | -11.841749 |
| Free Cashflow | -83,963,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,784 |
| Fullday Change | 0.1800003 |
| Fullday Change Percent | 0.7255151 |
| Fullday Price | 24.99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.03778 |
| Gross Profits | 16,985,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0212 |
| Held Percent Institutions | 0.38464 |
| Implied Shares Outstanding | 112,266,228 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China. |
| Long Name | Zai Lab Limited |
| Market | us_market |
| Market Cap | 2,805,532,928 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_271123063 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -188,212,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,014,480,974 |
| Number Of Analyst Opinions | 12 |
| Open | 24.82 |
| Operating Cashflow | -133,384,000 |
| Operating Margins | -0.71948 |
| Phone | 86 21 6163 2588 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 24.99 |
| Post Market Time | 1,791,576,072 |
| Previous Close | 24.81 |
| Price Eps Current Year | -11.381854 |
| Price Hint | 2 |
| Price To Book | 4.620932 |
| Price To Sales Trailing12 Months | 6.2398696 |
| Profit Margins | -0.41861 |
| Quick Ratio | 1.611 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.1800003 |
| Regular Market Change Percent | 0.7255151 |
| Regular Market Day High | 25.88 |
| Regular Market Day Low | 24.35 |
| Regular Market Day Range | 24.35 - 25.88 |
| Regular Market Open | 24.82 |
| Regular Market Previous Close | 24.81 |
| Regular Market Price | 24.99 |
| Regular Market Time | 1,791,576,000 |
| Regular Market Volume | 1,024,847 |
| Return On Assets | -0.14745 |
| Return On Equity | -0.26911 |
| Revenue Growth | -0.033 |
| Revenue Per Share | 4.057 |
| Sand P52 Week Change | 0.17383456 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 112,266,228 |
| Shares Percent Shares Out | 0.0727 |
| Shares Short | 8,156,879 |
| Shares Short Previous Month Date | 1,786,665,600 |
| Shares Short Prior Month | 7,465,887 |
| Short Name | Zai Lab Limited |
| Short Percent Of Float | 0.074099995 |
| Short Ratio | 8.05 |
| Source Interval | 15 |
| Symbol | ZLAB |
| Target High Price | 50.0 |
| Target Low Price | 24.25 |
| Target Mean Price | 33.14 |
| Target Median Price | 31.84 |
| Total Cash | 617,521,984 |
| Total Cash Per Share | 5.501 |
| Total Debt | 254,576,000 |
| Total Revenue | 449,614,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.589926 |
| Two Hundred Day Average Change | 4.400074 |
| Two Hundred Day Average Change Percent | 0.21370034 |
| Type Disp | Equity |
| Volume | 1,024,847 |
| Website | https://www.zailaboratory.com |
| Zip | 201,203 |